DEA Telemedicine Rules for Prescribing Controlled Substances

Through December 31, 2026, DEA rules for prescribing controlled substances via telemedicine let any DEA-registered practitioner prescribe Schedule II through V medications to a patient they have never seen in person, provided every other federal and state requirement is met.¹ After that date, the pre-pandemic in-person evaluation mandate returns for new patient relationships unless the DEA finalizes its proposed permanent framework first.²

What You Can Prescribe Remotely Right Now

The current extension covers all schedules of controlled substances that a DEA-registered practitioner is otherwise authorized to prescribe, from Schedule II opioids and stimulants down through Schedule V medications. The prescription still has to comply with every other federal and state rule that would apply if the visit had happened in the office.¹

The default format for the encounter is audio-video: both practitioner and patient can see and hear each other in real time. A phone call alone will not support most controlled substance prescriptions.¹

One exception matters. Practitioners may use audio-only encounters, including a standard phone call, to prescribe Schedule III through V narcotic medications approved by the FDA for opioid use disorder treatment. Buprenorphine is the main drug this covers.²

The Baseline That Returns Without a New Rule

The waived requirement comes from the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which amended the Controlled Substances Act to bar any controlled substance prescription over the internet without a “valid prescription,” defined as one issued after at least one in-person medical evaluation.³⁴ The statute carries a small set of built-in exceptions: prescribing during a declared public health emergency, treatment by a VA practitioner, treatment at a DEA-registered hospital or clinic, and limited medical emergencies. The public health emergency exception is the legal hook the DEA has been using to keep the flexibilities alive.

If the DEA does not finalize permanent regulations by December 31, 2026, the in-person mandate applies again to every new telemedicine patient relationship involving a controlled substance.²

Licensing and DEA Registration Across State Lines

A DEA registration is the floor, not the ceiling. The Controlled Substances Act generally requires a separate DEA registration in each state where the patient is physically located at the time of prescribing. If you are registered in New York and your patient is sitting in New Jersey when you see them, you generally need a New Jersey DEA registration as well.⁵

A COVID-era temporary exception allows practitioners to prescribe in states where they lack a DEA registration, provided they hold at least one DEA registration and are otherwise permitted to practice in the patient’s state under that state’s law.⁵ State medical licensing is a separate question. You need a license to practice medicine in the state where the patient is located, and state rules vary; some states participate in interstate compacts or issue special telehealth licenses.

PDMP Checks, Identity, and Consent

Before writing a controlled substance prescription over telemedicine, check the Prescription Drug Monitoring Program database in the state where the patient is located. Most states require a PDMP check for controlled substance prescriptions whether the visit was remote or in person, though the specifics differ by state.

Verify the patient’s identity and document informed consent for telehealth in the medical record. For prescriptions tied to opioid use disorder treatment, the dispensing pharmacist has an independent duty to verify the patient’s identity using a government-issued photo ID or equivalent.⁶

Schedule II: No Refills, But Multiple Prescriptions Are Allowed

Federal law prohibits refills on Schedule II prescriptions. Every fill needs a new prescription. A practitioner may write multiple prescriptions on the same day covering up to a 90-day total supply, but each one has to carry a “do not fill until” date, and the practitioner must determine that issuing them together does not create an undue risk of diversion.⁷ State law has to permit the practice, and some states set shorter supply limits.

Emergency Oral Prescriptions for Schedule II

In a true emergency where a patient needs a Schedule II medication immediately and a written or electronic prescription is not feasible, the practitioner may authorize the prescription by phone. The pharmacist can dispense only the quantity needed for the emergency period.⁸

Within seven days the prescriber must deliver a written follow-up prescription to the dispensing pharmacy, marked “Authorization for Emergency Dispensing” and showing the date of the original oral order. If the follow-up does not arrive, the pharmacist must notify the nearest DEA office. If the emergency prescription was only partially filled, the remainder must be filled within 72 hours or a new prescription is required.⁸

Schedule III and IV Refill Cap

Schedule III and IV prescriptions can be refilled, but only up to five times within six months from the date the original prescription was issued.⁹ Whichever comes first ends the prescription: five refills, or six months. A prescriber can authorize additional refills on the original prescription by calling the pharmacy, but the five-refill and six-month caps still apply.

Schedule V substances generally carry fewer restrictions. The five-refill, six-month regulation applies by its text to Schedules III and IV; specific Schedule V rules depend on the substance and state law.

The Pharmacist’s Corresponding Responsibility

A telemedicine prescription still has to clear the pharmacy. Federal regulations impose a “corresponding responsibility” on the dispensing pharmacist to ensure controlled substances are dispensed properly, and a pharmacist who fills a suspicious prescription faces the same category of enforcement exposure as the prescriber who wrote it. For an online pharmacy, only a pharmacist working on behalf of a pharmacy holding a modified DEA registration for online operations can legally fill the prescription.⁶

Penalties for Getting It Wrong

Prescribing outside the Controlled Substances Act carries heavy consequences. A practitioner who knowingly distributes or dispenses a Schedule I or II controlled substance without authorization can face up to 20 years in federal prison for a first offense, up to 30 years for a second felony drug offense, and fines up to $1 million for an individual. If death or serious bodily injury results, the minimum sentence rises to 20 years.¹⁰

Short of criminal prosecution, the DEA can revoke or suspend a controlled substance registration based on a felony drug conviction, loss of state medical licensure, false information on a registration application, or conduct inconsistent with the public interest.¹¹ Losing DEA registration effectively ends the ability to prescribe any controlled substance.

Permanent Carve-Outs That Survive the Deadline

Two permanent rules took effect on December 31, 2025, and remain in force regardless of what happens to the broader temporary framework.¹

The first, “Expansion of Buprenorphine Treatment via Telemedicine Encounter,” permanently allows practitioners to prescribe Schedule III through V controlled substances approved by the FDA for opioid use disorder treatment, primarily buprenorphine, via telemedicine including audio-only encounters.¹²

The second, “Continuity of Care via Telemedicine for Veterans Affairs Patients,” permanently allows VA practitioners to keep prescribing controlled substances via telemedicine to established patients.

The Proposed Special Registration Framework

On January 17, 2025, the DEA published a proposed rule that would create a permanent pathway for telemedicine prescribing through a new “special registration” system, dropping the mandatory in-person evaluation for practitioners who obtain one.¹³ The proposal has three tiers:

A Telemedicine Prescribing Registration for Schedule III through V prescribing via telemedicine without an in-person visit.
An Advanced Telemedicine Prescribing Registration extending that authority to Schedule II substances, but limited to specialized practitioners such as psychiatrists and hospice care physicians who can show a legitimate need.
A Telemedicine Platform Registration authorizing online telemedicine platforms to dispense Schedule II through V controlled substances through practitioners holding one of the individual registrations above.

All three tiers would require prescriptions to be issued electronically, and every telemedicine encounter would use audio-video, with an audio-only exception for buprenorphine prescribing for opioid use disorder after an initial video visit. Applicants would need at least one conventional DEA registration and a license to practice in the patient’s state.¹³

The proposal would also require a nationwide PDMP check across all 50 states and U.S. territories for any prescription issued under a special registration. That nationwide requirement has a delayed effective date of three years after the final rule takes effect, with interim requirements to check the PDMP in the patient’s state, the practitioner’s state, and any state with a reciprocity agreement.¹³

The DEA has said it extended the flexibilities through 2026 specifically to review public comments on this proposal and finalize a rule. If it does, practitioners will need to apply and come into compliance with the new registration, record-keeping, and security requirements. If it does not, the only remaining routes for prescribing controlled substances to a patient you have never examined in person will be the permanent buprenorphine and VA carve-outs.

1
United States Drug Enforcement Administration. DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care
2
Federal Register. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
3
Department of Justice. H.R. 6353 – Ryan Haight Online Pharmacy Consumer Protection Act of 2008
4
Office of the Law Revision Counsel. 21 USC 829 – Prescriptions
5
Drug Enforcement Administration Diversion Control Division. Telemedicine State Registration Requirements
6
eCFR. 21 CFR Part 1306 – Prescriptions
7
eCFR. 21 CFR 1306.12 – Refilling Prescriptions; Issuance of Multiple Prescriptions
8
eCFR. 21 CFR Part 1306 – Controlled Substances Listed in Schedule II
9
eCFR. 21 CFR 1306.22 – Refilling of Prescriptions
10
Office of the Law Revision Counsel. 21 USC 841 – Prohibited Acts A
11
GovInfo. 21 USC 824 – Denial, Revocation, or Suspension of Registration
12
Federal Register. Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
13
Federal Register. Special Registrations for Telemedicine and Limited State Telemedicine Registrations